An article from
News roundup
Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.
Published June 22, 2026
Getty Images
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.
586 words~3 min read
